1.Very Late Stent Thrombosis after Drug-Eluting Stent Implantation in a Patient without Aspirin and Clopidogrel Resistance.
Sang Yup LIM ; Ki Seok KIM ; Seung Jae JOO ; Myung Ho JEONG
Journal of Korean Medical Science 2008;23(3):556-559
Very late stent thrombosis (VLST) after implantation of drug-eluting stent is rare, but very fatal complication after percutaneous coronary intervention. We report a case of VLST of a sirolimus-eluting Cypher(TM) stent (Cordis, Johnson and Johnson) presenting as acute ST elevation myocardial infarction at 26 months after deployment with continued combined dual antiplatelet medication of aspirin and clopidogrel. The patient did not show anti-platelet resistance.
Aged
;
Angina Pectoris/*therapy
;
Aspirin/*therapeutic use
;
Coronary Angiography
;
Coronary Thrombosis/drug therapy/*etiology/radiography
;
Drug Resistance
;
Drug-Eluting Stents/*adverse effects
;
Electrocardiography
;
Female
;
Humans
;
Platelet Aggregation Inhibitors/*therapeutic use
;
Ticlopidine/*analogs & derivatives/therapeutic use
;
Time Factors
2.Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents.
Jang Won SON ; Ung KIM ; Jong Seon PARK ; Young Jo KIM ; Jae Sik JANG ; Tae Hyun YANG ; Dong Soo KIM ; Dong Kie KIM ; Sang Hoon SEOL ; Doo Il KIM ; Chang Wook NAM ; Seung Ho HUR ; Kwon Bae KIM
The Korean Journal of Internal Medicine 2013;28(1):72-80
BACKGROUND/AIMS: The Taxus Liberte stent (Boston Scientific Co.) evolved from the Taxus Express stent, with enhanced stent deliverability and uniform drug delivery. This study was designed to compare angiographic and clinical outcomes in real-world practice between the Taxus Liberte and Taxus Express stents. METHODS: Between 2006 and 2008, 240 patients receiving the Taxus Liberte stent at three centers were registered and compared to historical control patients who had received the Taxus Express stent (n = 272). After propensity score matching, 173 patients treated with the Taxus Liberte stent and the same number of patients treated with the Taxus Express stent were selected. The primary outcome was a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), ischemia driven target vessel revascularization (TVR), and stent thrombosis (ST) at 1 year. An additional angiographic assessment was conducted at 9 to 12 months. RESULTS: The study showed no significant difference between the Taxus Express and Taxus Liberte stents (death, 1.73% vs. 2.31%, p = 1.000; MI, 0% vs. 1.73%, p = 0.2478; TVR, 2.31% vs. 1.16%, p = 0.6848; and ST, 0% vs. 1.16%, p = 0.4986). The total MACE rate at 1 year did not differ between the groups (4.05% in Taxus Express vs. 4.05% in Taxus Liberte, p = 1.000). In addition, the binary restenosis rate did not differ (2.25% in Taxus Express vs. 1.80% in Taxus Liberte, p = 0.6848). CONCLUSIONS: In real-world experience with the two Taxus stent designs, both stents showed similarly good clinical and angiographic outcomes at 1 year. A long-term follow-up study is warranted.
Aged
;
Angioplasty, Balloon, Coronary/adverse effects/*instrumentation/mortality
;
Cardiovascular Agents/administration & dosage
;
Chi-Square Distribution
;
Coronary Angiography
;
Coronary Artery Disease/mortality/radiography/*therapy
;
Coronary Restenosis/etiology/mortality
;
Coronary Thrombosis/etiology/mortality
;
*Drug-Eluting Stents
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myocardial Infarction/etiology/mortality
;
Paclitaxel/*administration & dosage
;
Propensity Score
;
Prosthesis Design
;
Registries
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Stainless Steel
;
Time Factors
;
Treatment Outcome
3.Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis.
Bong Ki LEE ; Young Hak KIM ; Duk Woo PARK ; Sung Cheol YUN ; Jung Min AHN ; Hae Geun SONG ; Jong Young LEE ; Won Jang KIM ; Soo Jin KANG ; Seung Whan LEE ; Cheol Whan LEE ; Jae Hwan LEE ; In Whan SEONG ; Seong Wook PARK ; Seung Jung PARK
Journal of Korean Medical Science 2012;27(12):1499-1506
This was designed to assess the outcomes of side branch (SB) stenosis after implantation of three drug-eluting stents (DES). From 2,645 patients in the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Trial, 788 patients had 923 bifurcation lesions with SB > or = 1.5 mm were included. SB was treated in 150 lesions, including 35 (3.8%) receiving SB stenting. Of untreated SB with baseline stenosis < 50%, the incidences of periprocedural SB compromise was similar in the zotarolimus (15.8%), sirolimus (17.2%), and paclitaxel (16.6%) stent groups (P = 0.92). At follow-up angiography, delayed SB compromise occurred in 13.9%, 3.2%, and 9.4% (P = 0.010) of these groups. When classified into four groups (< 50%, 50%-70%, 70%-99%, and 100%), 9.0% of untreated SB were worsened, whereas improvement and stationary were observed in 9.6% and 81.4%. In a multivariable logistic regression model, main branch (MB) stenosis at follow-up (%) was the only independent predictor of SB stenosis worsening (odds ratio, 1.03; 95% confidence interval, 1.01-1.04; P < 0.001). After MB stenting in bifurcation lesions, a minority of SB appears to worsen. DES with strong anti-restenotic efficacy may help maintain SB patency.
Acute Disease
;
Aged
;
Blood Vessels/physiopathology
;
Cardiovascular Agents/*therapeutic use
;
Coronary Angiography
;
Coronary Stenosis/*drug therapy/physiopathology/radiography
;
Drug-Eluting Stents/*adverse effects
;
Female
;
Follow-Up Studies
;
Humans
;
Logistic Models
;
Male
;
Middle Aged
;
Myocardial Infarction/etiology/radiography
;
Myocardial Revascularization
;
Odds Ratio
;
Paclitaxel/*therapeutic use
;
Predictive Value of Tests
;
Sirolimus/*analogs & derivatives/*therapeutic use
;
Thrombosis/etiology
;
Treatment Outcome
4.Seven-Year Clinical Outcomes of Sirolimus-Eluting Stent Versus Bare-Metal Stent: A Matched Analysis From A Real World, Single Center Registry.
Ung KIM ; Jong Seon PARK ; Sang Hee LEE ; Dong Gu SHIN ; Young Jo KIM
Journal of Korean Medical Science 2013;28(3):396-401
The aim of this study is to compare clinical outcomes for seven years, between sirolimus-eluting stent (SES) and bare metal stent (BMS). During the BMS and drug-eluting stent (DES) transition period (from April 2002 to April 2004), 434 consecutive patients with 482 lesions underwent percutaneous coronary intervention, using BMS or SES. Using propensity score matching, 186 patients with BMS and 166 patients with SES were selected. Seven year clinical outcomes of major adverse cardiac events (MACE), such as cardiac death, myocardial infarction (MI) and ischemia-driven target vessel revascularization (TVR), and angiographic definite stent thrombosis (ST) were compared. At one-year follow up, patients with SES showed significantly lower MACE (9.1% in BMS vs 3.0% in SES, P = 0.024). However, cumulative MACE for 7 yr was not significantly different between two groups (24.7% in BMS vs 17.4% in SES, P = 0.155). There was no significant difference in MI, TVR, death and ST. The TVR were gradually increased from 1 to 7 yr in SES, on the contrary to that of BMS. In conclusion, although SES showed better clinical outcomes in the early period after implantation, it did not show significant benefits in the long-term follow up, compared with that of BMS.
Aged
;
Angioplasty, Balloon, Coronary/adverse effects/*methods
;
Coronary Angiography
;
Coronary Stenosis/mortality/radiography/*therapy
;
Databases, Factual
;
*Drug-Eluting Stents
;
Female
;
Follow-Up Studies
;
Humans
;
Ischemia/etiology
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Myocardial Infarction/etiology
;
Myocardial Revascularization
;
Registries
;
Sirolimus/*therapeutic use
;
*Stents
;
Thrombosis/etiology